Search results
Results from the WOW.Com Content Network
TAP Pharmaceuticals was formed in 1977 as a joint venture between the two global pharmaceutical companies, Abbott Laboratories and Takeda Pharmaceutical Co. and was dissolved in 2008; its two most lucrative products were proton-pump inhibitor lansoprazole (Prevacid) and the prostate cancer drug, leuprorelin (Lupron). [1]
Between 2010 and 2013, the FDA updated the Lupron drug label to include new safety information on the risk of thromboembolism, loss of bone density and convulsions. [58] The FDA then asserted that the benefits of leuprorelin outweigh its risks when used according to its approved labeling.
Diversion, abuse, and a relatively high rate of overdose deaths in comparison to other drugs of its group. This drug continues to be available in most of the world including the US, but under strict controls. Terfenadine (Seldane, Triludan) 1997–1998 France, South Africa, Oman, others, US Prolonged QT interval; ventricular tachycardia [2] [3]
A category for drugs withdrawn from the market after marketing commenced for any reason (voluntarily or involuntarily). For drug candidates that were abandoned prior to being marketed due to side effects, lack of efficacy, superior competitors, or other reasons, see Category:Abandoned drugs
Moreover, 6% of flutamide-treated patients discontinued the medication due to diarrhea, whereas only 0.5% of bicalutamide-treated patients did so. [41] In the case of antiandrogen monotherapy for prostate cancer, the rates of diarrhea are 5 to 20% for flutamide, 2 to 5% for bicalutamide, and 2 to 4% for nilutamide . [ 41 ]
The leuprorelin is given by intramuscular injection and the norethisterone acetate is taken by mouth. [ 1 ] The co-packaged medication was approved for medical use in the United States in December 2012.
(Reuters) - About one in eight adults have taken a drug belonging to the GLP-1 class of medications for weight loss and related conditions, a poll by Kaiser Family Foundation (KFF) showed on Friday.
The problem began in 2012, when the process for making tetrazole, a chemical intermediate in the production of various angiotensin II inhibitor medications for hypertension (popularly known by their common drug name suffix "sartan") was changed by generic drug manufacturers in favor of several cheaper and more efficient processes.